Analytical Data
-
Gene name
PKIa
- Application
-
Alternative Names
PKIa；PRKACN1；cAMP-dependent Protein kinase inhibitor alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P61925
-
Expression Region
2-76aa
-
AA Sequence
TDVETTYAD FIASGRTGRR NAIHDILVSS ASGNSNELAL KLAGLDINKT EGEEDAQRSS TEQSGEAQGE AAKSES
-
Molecular Weight
7.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PKIa (Protein Kinase A type I alpha) is a crucial enzyme involved in various cellular signaling pathways that regulate key physiological processes such as metabolism, cell growth, and differentiation. The research focus on PKIa stems from its significant role in the cyclic AMP (cAMP) signaling cascade, where it serves as a major effector that transmits signals from extracellular stimuli to intracellular responses. Dysregulation of PKIa activity has been implicated in numerous diseases, including cancer, cardiovascular disorders, and neurological conditions, making it an important target for therapeutic intervention. Recent advancements in genetic engineering and recombinant protein technology have facilitated the production of PKIa in heterologous systems, enabling researchers to investigate its structural and functional properties in detail. Understanding the molecular mechanisms underlying PKIa's activity could provide insights into its role in disease and pave the way for the development of specific inhibitors or activators as potential drugs. The ongoing research aims to elucidate the intricate regulatory mechanisms governing PKIa, assess its interactions with various substrates, and explore its potential as a biomarker for disease progression. The successful characterization of PKIa as a recombinant protein not only enhances our understanding of its biological significance but also contributes to the broader field of signal transduction research, ultimately aiming to translate these findings into clinical applications.
